JMP Securities Trims CureVac (NASDAQ:CVAC) Target Price to $34.00

CureVac (NASDAQ:CVACGet Rating) had its price objective decreased by JMP Securities from $37.00 to $34.00 in a research report sent to investors on Thursday, MarketBeat reports. JMP Securities currently has a market outperform rating on the stock.

CureVac Stock Down 4.0 %

Shares of NASDAQ:CVAC opened at $8.16 on Thursday. The company has a 50-day simple moving average of $7.94 and a 200 day simple moving average of $11.99. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. CureVac has a 52-week low of $6.90 and a 52-week high of $50.09.

Institutional Investors Weigh In On CureVac

Hedge funds have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale acquired a new stake in CureVac during the second quarter worth approximately $27,000. Signaturefd LLC lifted its position in CureVac by 226.3% during the first quarter. Signaturefd LLC now owns 2,392 shares of the company’s stock worth $47,000 after acquiring an additional 1,659 shares during the last quarter. Quadrant Capital Group LLC lifted its position in CureVac by 115.8% during the first quarter. Quadrant Capital Group LLC now owns 2,931 shares of the company’s stock worth $57,000 after acquiring an additional 1,573 shares during the last quarter. Amundi acquired a new stake in CureVac during the second quarter worth approximately $87,000. Finally, Virtus ETF Advisers LLC lifted its position in CureVac by 90.6% during the second quarter. Virtus ETF Advisers LLC now owns 7,676 shares of the company’s stock worth $104,000 after acquiring an additional 3,648 shares during the last quarter.

About CureVac

(Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.

Recommended Stories

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.